FDA
-
-
-
-
-
-
-
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
-
-
-
-
-
-
-
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
-
-
-
-
-
-
-
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
-
-
-
-
-
-
-
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

